SB17170 for Idiopathic Pulmonary Fibrosis (IPF)
Part of Lungs & breathing clinical trials.
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years or older.
- You have been diagnosed with IPF, confirmed by a special CT scan of your chest.
- Your lung function test (FVC) is at least 45% of what is expected for someone your age and size.
- You have no other major lung disease like IPF caused by arthritis or other connective tissue diseases.
- You have not had a sudden worsening of your IPF in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
This trial tests a new drug called SV001 to see if it is safe and tolerable for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and meet certain health criteria, this study may help find new treatment options.
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This study tests an experimental pill called SYH2059 for people with IPF, a condition that causes lung scarring and makes breathing harder. The goal is to see if the pill is safe and can help slow down the disease.
This study tests a new medicine called AGMB-447 for people with idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes scarred and breathing becomes harder. The goal is to see if the treatment is safe and helps improve lung function.
Hear when a new IPF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.